Jean R Lowe1, Rebecca E Rieger2, Natalia C Moss2, Ronald A Yeo2, Sarah Winter3, Shrena Patel3, John Phillips4, Richard Campbell5, Shawna Baker3, Sean Gonzales1, Robin K Ohls6. 1. Department of Pediatrics, University of New Mexico School of Medicine, Albuquerque, NM. 2. Department of Psychology, University of New Mexico, Albuquerque, NM. 3. Department of Pediatrics, University of Utah, Salt Lake City, UT. 4. Department of Neurology, University of New Mexico, Albuquerque, NM. 5. Department of Psychiatry, University of New Mexico, Albuquerque, NM. 6. Department of Pediatrics, University of New Mexico School of Medicine, Albuquerque, NM. Electronic address: rohls@salud.unm.edu.
Abstract
OBJECTIVE: To evaluate the impact of erythropoiesis-stimulating agents (ESAs) administered during initial hospitalization and family demographic factors on behavior at 3.5-4 years of age. STUDY DESIGN:Children were enrolled who had previously participated in a randomized study of ESAs (n = 35) orplacebo (n = 14) in infants born preterm with birth weights of 500-1250g. A term healthy control group (n = 22) also was recruited. Behavior was evaluated by parent report with the Behavioral Assessment System of Children-2. Principal component analyses identified 2 demographic factors, a Socioeconomic Composite (SEC) and a Family Stress Composite. A multivariate general linear model evaluated the impact of study group and sex on the 4 composite scales of the Behavioral Assessment System of Children-2. Demographic factors were treated as covariates and interactions with study group (ESA, placebo, and term) were examined. RESULTS: The ESA group had significantly better scores than the placebo group on behavioral symptoms (P = .04) and externalizing scales (P = .04). An interaction was observed between study group and SEC (P = .001). A beneficial effect of ESAs was maximal in the children with lower SEC scores. CONCLUSIONS: The beneficial effects of ESAs on childhood behavior were maximal in children with lower SEC scores. ESAs seemed to ameliorate the adverse impact of lower SEC on behavioral domains seen in the placebo group. This effect was independent of the beneficial effect of ESAs on global cognition we reported previously. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01207778 and NCT00334737.
RCT Entities:
OBJECTIVE: To evaluate the impact of erythropoiesis-stimulating agents (ESAs) administered during initial hospitalization and family demographic factors on behavior at 3.5-4 years of age. STUDY DESIGN:Children were enrolled who had previously participated in a randomized study of ESAs (n = 35) or placebo (n = 14) in infants born preterm with birth weights of 500-1250 g. A term healthy control group (n = 22) also was recruited. Behavior was evaluated by parent report with the Behavioral Assessment System of Children-2. Principal component analyses identified 2 demographic factors, a Socioeconomic Composite (SEC) and a Family Stress Composite. A multivariate general linear model evaluated the impact of study group and sex on the 4 composite scales of the Behavioral Assessment System of Children-2. Demographic factors were treated as covariates and interactions with study group (ESA, placebo, and term) were examined. RESULTS: The ESA group had significantly better scores than the placebo group on behavioral symptoms (P = .04) and externalizing scales (P = .04). An interaction was observed between study group and SEC (P = .001). A beneficial effect of ESAs was maximal in the children with lower SEC scores. CONCLUSIONS: The beneficial effects of ESAs on childhood behavior were maximal in children with lower SEC scores. ESAs seemed to ameliorate the adverse impact of lower SEC on behavioral domains seen in the placebo group. This effect was independent of the beneficial effect of ESAs on global cognition we reported previously. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01207778 and NCT00334737.
Authors: Shenandoah Robinson; Christopher J Corbett; Jesse L Winer; Lindsay A S Chan; Jessie R Maxwell; Christopher V Anstine; Tracylyn R Yellowhair; Nicholas A Andrews; Yirong Yang; Laurel O Sillerud; Lauren L Jantzie Journal: Exp Neurol Date: 2017-12-26 Impact factor: 5.330
Authors: Charles Gasparovic; Arvind Caprihan; Ronald A Yeo; John Phillips; Jean R Lowe; Richard Campbell; Robin K Ohls Journal: Pediatr Radiol Date: 2018-01-15